{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:26:11Z","timestamp":1792808771870,"version":"4.5.0"},"reference-count":40,"publisher":"Bioscientifica","issue":"7","funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR069128"],"award-info":[{"award-number":["RS-2022-NR069128"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We aimed to determine the prevalence and clinical significance of targetable gene fusions in patients with radioiodine-refractory thyroid cancer. This multicenter retrospective cohort study enrolled 111 patients from five tertiary medical centers, with molecular profiling performed using targeted next-generation sequencing. The analysis revealed that 58 (52.3%) patients possessed BRAFV600E mutation, while 25 (22.5%) had RAS mutations. Among the 20 (18.0%) patients with gene fusions, 13 had RET fusions, three had NTRK fusions, one had a BRAF fusion, and three had nondriver gene fusions. The group with targetable gene fusions was significantly younger compared to those with BRAF or RAS mutations (P &amp;lt; 0.001) and predominantly had classic papillary thyroid carcinoma. Furthermore, targetable gene fusions were detected in 30.8% of patients with refractory thyroid cancer harboring wild-type BRAF. More than half of the patients received systemic tyrosine kinase inhibitor therapy and three patients with confirmed RET or NTRK fusions achieved meaningful clinical benefit with selective agents. These findings suggest that a stepwise molecular testing strategy \u2013 initiating with BRAF single gene analysis followed by next-generation sequencing for assessing targetable gene fusions \u2013 may be a rational approach, particularly for younger patients with papillary thyroid carcinoma, for identifying candidates for precision therapy. This supports the integration of molecular profiling into routine clinical practice for radioiodine-refractory thyroid cancer and emphasizes its utility in guiding personalized treatment decisions in this challenging disease subset.<\/jats:p>","DOI":"10.1530\/erc-25-0089","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T10:23:21Z","timestamp":1750933401000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":4,"title":["Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter study"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5074-3561","authenticated-orcid":true,"given":"Jungmin","family":"Yoo","sequence":"first","affiliation":[{"name":"Division of Endocrinology & Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine 1 , ,","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-8859","authenticated-orcid":true,"given":"Mijin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine 2 , ,","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1617-3171","authenticated-orcid":true,"given":"Hee Kyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School 3 , , ,","place":["Hwasun, Jeollanam-do, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1048-7978","authenticated-orcid":true,"given":"Dong Yeob","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine 4 , ,","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-107X","authenticated-orcid":true,"given":"Min Ji","family":"Jeon","sequence":"additional","affiliation":[{"name":"Division of Endocrinology & Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine 1 , ,","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-9457","authenticated-orcid":true,"given":"Bo Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine 2 , ,","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-1345","authenticated-orcid":true,"given":"Ho-Cheol","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School 3 , , ,","place":["Hwasun, Jeollanam-do, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7449-3683","authenticated-orcid":true,"given":"Jaekyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea 5 , ,","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-6482","authenticated-orcid":true,"given":"Dong-Jun","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea 5 , ,","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8404-7759","authenticated-orcid":true,"given":"Won Gu","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology & Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine 1 , ,","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"2026070905442753300_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910787","article-title":"Descriptive analysis of common fusion mutations in papillary thyroid carcinoma in Hungary","volume":"25","author":"Armos","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026070905442753300_bib2","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.3390\/curroncol30030229","article-title":"Initial experiences of selective RET inhibitor selpercatinib in adults with metastatic differentiated thyroid carcinoma and medullary thyroid carcinoma: real-world case series in Korea","volume":"30","author":"Baek","year":"2023","journal-title":"Curr Oncol"},{"key":"2026070905442753300_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2026070905442753300_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"key":"2026070905442753300_bib5","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4143\/crt.2023.682","article-title":"Clinicopathological characteristics of NRG1 fusion-positive solid tumors in Korean patients","volume":"55","author":"Cha","year":"2023","journal-title":"Cancer Res Treat"},{"key":"2026070905442753300_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13046-020-01757-x","article-title":"The molecular and gene\/miRNA expression profiles of radioiodine resistant papillary thyroid cancer","volume":"39","author":"Colombo","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"2026070905442753300_bib7","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK Fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026070905442753300_bib8","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae158","article-title":"Single-institution experience of larotrectinib therapy for patients with NTRK fusion-positive thyroid carcinoma","volume":"8","author":"Elghawy","year":"2024","journal-title":"J Endocr Soc"},{"key":"2026070905442753300_bib9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070905442753300_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0304-3835(00)00697-2","article-title":"Thyroid cancer","volume":"163","author":"Gimm","year":"2001","journal-title":"Cancer Lett"},{"key":"2026070905442753300_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/thy.2021.0217","article-title":"High prevalence of gene fusions and copy number alterations in pediatric radiation therapy-induced papillary and follicular thyroid carcinomas","volume":"32","author":"Hess","year":"2022","journal-title":"Thyroid"},{"key":"2026070905442753300_bib12","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1158\/1078-0432.CCR-17-1183","article-title":"Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence","volume":"23","author":"Ibrahimpasic","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026070905442753300_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12020-019-01842-y","article-title":"Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis","volume":"64","author":"Jeon","year":"2019","journal-title":"Endocrine"},{"key":"2026070905442753300_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1210\/clinem\/dgad500","article-title":"Fusion oncogenes in patients with locally advanced or distant metastatic differentiated thyroid cancer","volume":"109","author":"Ju","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905442753300_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4143\/crt.2022.891","article-title":"Validation and clinical application of ONCOaccuPanel for targeted next-generation sequencing of solid tumors","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"2026070905442753300_bib16","doi-asserted-by":"crossref","first-page":"14035","DOI":"10.1007\/s00432-023-05134-x","article-title":"NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer","volume":"149","author":"Koehler","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026070905442753300_bib17","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.tranon.2019.07.017","article-title":"Cancer panel assay for precision oncology clinic: results from a 1-year study","volume":"12","author":"Kwon","year":"2019","journal-title":"Transl Oncol"},{"key":"2026070905442753300_bib18","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Investig"},{"key":"2026070905442753300_bib19","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3803\/EnM.2023.1758","article-title":"Comparative analysis of driver mutations and transcriptomes in papillary thyroid cancer by region of residence in South Korea","volume":"38","author":"Lee","year":"2023","journal-title":"Endocrinol Metab"},{"key":"2026070905442753300_bib20","doi-asserted-by":"crossref","first-page":"E1852","DOI":"10.1210\/jc.2013-2292","article-title":"Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer","volume":"98","author":"Nikiforova","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905442753300_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12859-015-0849-9","article-title":"The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes","volume":"17","author":"Pagan","year":"2016","journal-title":"BMC Bioinformatics"},{"key":"2026070905442753300_bib22","article-title":"Real-world experience of NTRK fusion-positive thyroid cancer","volume":"6","author":"Park","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026070905442753300_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.11106\/ijt.2024.17.1.1","article-title":"Korean Thyroid Association Guidelines on the management of differentiated thyroid cancers; overview and summary 2024","volume":"17","author":"Park","year":"2024","journal-title":"Int J Thyroidol"},{"key":"2026070905442753300_bib24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamasurg.2018.1153","article-title":"Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules","volume":"153","author":"Patel","year":"2018","journal-title":"JAMA Surg"},{"key":"2026070905442753300_bib25","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026070905442753300_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070905442753300_bib27","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"key":"2026070905442753300_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3803\/EnM.2015.30.3.252","article-title":"Mutation profile of well-differentiated thyroid cancer in Asians","volume":"30","author":"Song","year":"2015","journal-title":"Endocrinol Metab"},{"key":"2026070905442753300_bib29","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.3390\/cancers13225846","article-title":"Mutation in genes encoding key functional groups additively increase mortality in patients with BRAF(V600E)-mutant advanced papillary thyroid carcinoma","volume":"13","author":"Song","year":"2021","journal-title":"Cancers"},{"key":"2026070905442753300_bib30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaoncol.2018.4616","article-title":"Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study","volume":"5","author":"Steward","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070905442753300_bib31","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1158\/0008-5472.CAN-21-0761","article-title":"Diverse oncogenic fusions and distinct gene expression patterns define the genomic landscape of pediatric papillary thyroid carcinoma","volume":"81","author":"Stosic","year":"2021","journal-title":"Cancer Res"},{"key":"2026070905442753300_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070905442753300_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/thy.2023.0363","article-title":"Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study","volume":"34","author":"Subbiah","year":"2024","journal-title":"Thyroid"},{"key":"2026070905442753300_bib34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American Joint Committee on Cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"2026070905442753300_bib35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/thy.2018.0597","article-title":"Controversies, consensus, and collaboration in the use of (131)i therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association","volume":"29","author":"Tuttle","year":"2019","journal-title":"Thyroid"},{"key":"2026070905442753300_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1530\/EJE-18-0653","article-title":"Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma","volume":"180","author":"van der Tuin","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2026070905442753300_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070905442753300_bib38","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"2026070905442753300_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070905442753300_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006239","article-title":"Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers","volume":"12","author":"Yoo","year":"2016","journal-title":"PLoS Genet"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/7\/ERC-25-0089.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/7\/ERC-25-0089.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0089\/145167\/erc-25-0089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0089\/145167\/erc-25-0089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:44:38Z","timestamp":1783590278000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/7\/e250089\/25945\/Next-generation-sequencing-of-targetable-gene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0089","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"article-number":"e250089"}}